Table 4.
Sensitivity analysis.
| Indicators | Before excluding trials | Excluded poor trials | Excluded over/under-estimation* | Excluded poor,over/under-estimation* | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trials | SM | OR(95%CI) | I2 | Trials | SM | OR (95%CI) | I2 | Trials | SM | OR (95%CI) | I2 | Trials | SM | OR (95%CI) | I2 | |
| Rh-Endostatin with Cisplatin | ||||||||||||||||
| Complete response | 59 | FEM | 2.29 [1.93, 2.71] | 0% | 25 | FEM | 2.28 [1.74, 2.98] | 0% | 56 | FEM | 2.24 [1.88, 2.67] | 0% | 24 | FEM | 2.21 [1.69, 2.90] | 0% |
| Treatment failure | 60 | FEM | 0.29 [0.25, 0.33] | 0% | 25 | FEM | 0.32 [0.26, 0.39] | 0% | 17 | FEM | 0.41 [0.31, 0.54] | 0% | 8 | FEM | 0.45 [0.31, 0.66] | 0% |
| Progressive disease | 50 | FEM | 0.27 [0.22, 0.34] | 0% | 23 | FEM | 0.31 [0.23, 0.42] | 0% | 39 | FEM | 0.31 [0.24, 0.41] | 0% | 19 | FEM | 0.32 [0.22, 0.46] | 0% |
| Quality of life | 32 | FEM | 3.01 [2.49, 3.63] | 0% | 13 | FEM | 2.76 [2.06, 3.69] | 0% | 14 | FEM | 1.99 [1.50, 2.66] | 0% | 6 | FEM | 1.93 [1.24, 2.99] | 0% |
| 1 OS rate | 3 | FEM | 3.32 [1.63, 6.75] | 0% | 2 | FEM | 2.98 [1.28, 6.92] | 0% | 1 | no | 2.17 [0.63, 7.44] | no | 1 | no | 2.17 [0.63, 7.44] | no |
| Neutropenia | 32 | FEM | 0.98 [0.79, 1.21] | 0% | 18 | FEM | 1.08 [0.81, 1.43] | 0% | 32 | FEM | 0.98 [0.79, 1.21] | 0% | 18 | FEM | 1.08 [0.81, 1.43] | 0% |
| Thrombocytopenia | 28 | FEM | 1.04 [0.80, 1.36] | 0% | 13 | FEM | 1.07 [0.71, 1.59] | 0% | 28 | FEM | 1.04 [0.80, 1.36] | 0% | 13 | FEM | 1.07 [0.71, 1.59] | 0% |
| Anemia | 10 | FEM | 1.29 [0.80, 2.09] | 0% | 9 | FEM | 1.45 [0.84, 2.50] | 0% | 10 | FEM | 1.29 [0.80, 2.09] | 0% | 9 | FEM | 1.45 [0.84, 2.50] | 0% |
| Gastrointestinal reactions | 49 | FEM | 1.14 [0.95, 1.36] | 0% | 22 | FEM | 1.03 [0.80, 1.34] | 0% | 49 | FEM | 1.14 [0.95, 1.36] | 0% | 22 | FEM | 1.03 [0.80, 1.34] | 0% |
| Hepatotoxicity | 28 | FEM | 1.07 [0.77, 1.48] | 0% | 21 | FEM | 0.98 [0.67, 1.44] | 0% | 28 | FEM | 1.07 [0.77, 1.48] | 0% | 21 | FEM | 0.98 [0.67, 1.44] | 0% |
| Nephrotoxicity | 28 | FEM | 1.06 [0.74, 1.53] | 0% | 21 | FEM | 0.94 [0.62, 1.44] | 0% | 28 | FEM | 1.06 [0.74, 1.53] | 0% | 21 | FEM | 0.94 [0.62, 1.44] | 0% |
| Cardiotoxicity | 21 | FEM | 1.06 [0.74, 1.53] | 0% | 19 | FEM | 1.39 [0.84, 2.31] | 0% | 21 | FEM | 1.06 [0.74, 1.53] | 0% | 19 | FEM | 1.39 [0.84, 2.31] | 0% |
| Fever | 20 | FEM | 0.98 [0.68, 1.41] | 0% | 10 | FEM | 1.04 [0.61, 1.76] | 0% | 20 | FEM | 0.98 [0.68, 1.41] | 0% | 10 | FEM | 1.04 [0.61, 1.76] | 0% |
| Thoracodynia | 12 | FEM | 1.01 [0.63, 1.60] | 0% | 5 | FEM | 0.92 [0.44, 1.93] | 0% | 12 | FEM | 1.01 [0.63, 1.60] | 0% | 5 | FEM | 0.92 [0.44, 1.93] | 0% |
| Neurotoxicity | 5 | FEM | 0.98 [0.36, 2.65] | 0% | 4 | FEM | 0.77 [0.21, 2.83] | 0% | 5 | FEM | 0.98 [0.36, 2.65] | 0% | 4 | FEM | 0.77 [0.21, 2.83] | 0% |
| Hemorrhage | 2 | FEM | 2.95 [0.45, 19.38] | 0% | 1 | no | 5.00 [0.23,107.35] | no | 2 | FEM | 2.95[0.45,19.38] | 0% | 1 | no | 5.00[0.23,107.35] | no |
| Hypertension | 3 | FEM | 4.13 [0.68, 25.10] | 0% | 2 | FEM | 3.72 [0.40, 34.48] | 0% | 3 | FEM | 4.13 [0.68,25.10] | 0% | 2 | FEM | 3.72 [0.40, 34.48] | 0% |
| Rh-Endostatin with Nedaplatin | ||||||||||||||||
| Complete response | 4 | FEM | 2.50 [1.31, 4.77] | 0% | 2 | FEM | 2.48 [1.10, 5.62] | 0% | 4 | FEM | 2.50 [1.31, 4.77] | 0% | 2 | FEM | 2.48 [1.10, 5.62] | 0% |
| Treatment failure | 4 | FEM | 0.29 [0.16, 0.51] | 0% | 2 | FEM | 0.34 [0.15, 0.78] | 0% | 2 | FEM | 0.35 [0.14, 0.89] | 0% | 1 | No | 0.36 [0.08, 1.57] | No |
| Progressive disease | 3 | FEM | 0.31 [0.12, 0.79] | 0% | 1 | No | 0.32 [0.08, 1.31] | No | 3 | FEM | 0.31 [0.12, 0.79] | 0% | 1 | No | 0.32 [0.08, 1.31] | No |
| Rh-Endostatin with Bleomycin | ||||||||||||||||
| Complete response | 4 | FEM | 1.73 [0.89, 3.37] | 0% | 1 | No | 1.64 [0.37, 7.30] | No | 4 | FEM | 1.73 [0.89, 3.37] | 0% | 1 | No | 1.64 [0.37, 7.30] | No |
| Treatment failure | 4 | FEM | 0.38 [0.20, 0.72] | 0 | 1 | No | 0.29 [0.09, 0.95] | No | 1 | No | 3.25 [0.52,20.37] | No | No | No | No | No |
| Progressive disease | 4 | FEM | 0.49 [0.20, 1.19] | 0 | 1 | No | 0.26 [0.05, 1.48] | No | 4 | FEM | 0.49 [0.20, 1.19] | 0 | 1 | No | 0.26 [0.05, 1.48] | No |
SM, statistical method; FEM, fixed-effects model; REM, random-effects model; OR, odds ratio; OS, overall survival; CI, confidence interval; Poor*, poor trials that had at least one domain being considered as high risk of bias; Over* or Under*, overestimated or underestimated trials in which results had significant differences and beneficial to Rh-endostatin group.